Company intelligence / Profile preview

RedHill Biopharma

Tel-Aviv, Israel

Ownership: Public · RDHL
Employees: ~53
Development stage: Commercial

Overview

RedHill has FDA-approved drugs including Talicia for H. pylori infection and Aemcolo for travelers' diarrhea. The company has an advanced R&D pipeline with late-stage clinical development candidates addressing unmet medical needs in gastrointestinal and infectious diseases.

Therapeutic areas: GastroenterologyOncologyImmunologyHematologyInfectious Diseases
Modalities: Small moleculesoral therapeutics
Industry: Biotech

Drug pipeline

7 assets

Talicia

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

U.S. government (for opaganib development)Cosmo Pharmaceuticals (manufacturing)HCR Collateral Management

Financials

Market cap: $2.2M
Total revenue: $2M
Enterprise value: $-712.3K

Beyond the preview

Go deeper on RedHill Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RedHill Biopharma.

Explore the full profile